Compounds for immunoproteasome inhibition
US9359398B2 · kind B2 · utility
0Cited by
72References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 1, 2011 |
| Grant date | Jun 7, 2016 |
| Priority date | — |
| Expiry date | May 7, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D405/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.